🇺🇸 FDA
Pipeline program

Semaglutide Extended-release for Injectable Suspension, 1 mg

15403/23-24

Phase 1 small_molecule active

Quick answer

Semaglutide Extended-release for Injectable Suspension, 1 mg for Diabetes Mellitus, Type 2 is a Phase 1 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Diabetes Mellitus, Type 2
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials